We collaborate with pharmaceutical companies, biotechs and CROs who seek innovative molecules fast. We are not selling software licences.
Aqemia and Sanofi signed an agreement to contribute to the discovery of effective treatments for COVID-19, in December 2020.
The long-term objective of Aqemia is to become a neo-pharma, that is, to seed a pipeline of in-house drug discovery projects. Those projects can be co-lead for licensing. We seek to spin-off the most promising ones into nimble biotech companies.
